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The efficacy and safety of the single dose oral loading regimen of propafenone for
pharmacological cardioversion of recent-onset atrial fibrillation (AFib) was evaluated by
analyzing the trials on the subject identified through a comprehensive literature search. Most
of the trials used a single dose of 600 mg for oral loading. The success rates ranged from 56%
to 83%, depending on the duration of AFib and follow-up after drug administration. The
conversion time ranged from 110 6 59 to 287 6 352 min, depending on the duration of
observation after drug administration. The single dose oral loading regimen of propafenone
was significantly more efficacious than placebo in the first 8 h after administration but not at
24 h. Compared with the intravenous regimen, the oral regimen resulted in fewer conversions
in the first 2 h, but both regimens were equally efficacious afterward. The oral propafenone
regimen was as efficacious as the single dose oral loading regimen of flecainide but was
superior to those of quinidine and amiodarone. The adverse effects reported were transient
arrhythmia, reversible QRS-complex widening, transient hypotension and mild noncardiac
side effects. The transient arrhythmias were chiefly at the time of conversion and included
appearance of atrial flutter, bradycardia, pauses and junctional rhythm. No life-threatening
proarrhythmic adverse effects were reported. The single oral loading dose of propafenone
appears to be highly effective for conversion of recent-onset AFib, with a relatively rapid effect
within 2 to 3 h and freedom from serious adverse effects. (J Am Coll Cardiol 2001;37:542–7)
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Atrial fibrillation (AFib) is the most common, clinically
significant arrhythmia (1–3). The symptoms in AFib are
chiefly governed by the fast ventricular rates, which can be
controlled by using the atrioventricular node-blocking drugs
or, ideally, by converting AFib to sinus rhythm (3–5).
Traditionally, the initial treatment of AFib has been limited
to controlling ventricular rates by using the atrioventricular
node-blocking drugs and waiting for spontaneous conver-
sion to sinus rhythm (6–8). However, restoration of sinus
rhythm by early cardioversion will result in early alleviation
of the patient’s symptoms, will lower the incidence of
thromboembolism, will eliminate the need for long-term
use of the atrioventricular node-blocking drugs and will
possibly result in earlier discharge from the hospital (9). The
electrophysiological remodeling, resulting primarily from
changes in atrial refractoriness, starts taking place within a
few hours of the persistent AFib and decreases the chances
of successful conversion to sinus rhythm; therefore, attempts
should be made to establish sinus rhythm as early as possible
(10).
The rate of spontaneous conversion to sinus rhythm
within the first 24 h is 30% to 50%, depending on the
duration of the AFib, and can be increased to 70% to 80%
by pharmacological cardioversion and to 80% to 90% by
electrical cardioversion (9,11,12). The pharmacological car-
dioversion of recent-onset AFib carries the advantage of
being simpler, more convenient and free of the need for
sedation (9,12). The drugs that have been used to convert
recent-onset AFib to sinus rhythm are class IA, class IC and
class III antiarrhythmic agents (9,13–16). The class IC
agents, propafenone and flecainide, have the advantage of
convenient, single oral loading dose administration with
minimum side effects (13–15,17). Propafenone is a potent
sodium channel blocker with weak beta-adrenergic blocking
and calcium channel blocking activities (class IC, II, IV)
(18–20). Based on the available literature, propafenone
administered as a single dose oral loading agent, if not
contraindicated, is a useful first line agent for the pharma-
cological cardioversion of recent-onset AFib with a favor-
able side effect profile (21–36).
PHARMACOKINETICS
More than 95% of orally administered propafenone is
absorbed through the gut, and the time to peak serum
concentration after ingestion is 2 to 3 h (20,37).
Propafenone is 95% protein bound, and the metabolism is
99% hepatic with an elimination half-life of 2 to 12 h
(38,39). The pharmacokinetics of propafenone is favorable
for a single loading-dose administration. Propafenone un-
dergoes extensive first-pass hepatic metabolism by cyto-
chrome P450 2D6 to 5-hydroxypropafenone (37). The
5-hydroxypropafenone is equivalent to propafenone as a
sodium channel blocker but is less potent as a beta-blocker
(40). The N-desalkylpropafenone is another metabolite of
propafenone and is formed by the non-P450 2D6 mediated
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metabolism. This compound is less potent as a sodium
channel blocker and as a beta-blocker. The full antiarrhyth-
mic effect of propafenone depends not only on the parent
compound but also on these metabolites, which provide a
strong rationale for the use of the single-dose, oral loading
regimen.
DATA COLLECTION
The Medline (National Library of Medicine) search of the
English-language literature was performed to identify the
trials evaluating the use of oral loading propafenone for
pharmacological cardioversion of recent-onset AFib. The
trials studied were selected if they had compared the oral
loading propafenone with placebo, intravenous propafenone
or other oral loading antiarrhythmic agents. The references
to the articles were examined for additional studies. All
trials were examined, and data were manually extracted to
provide a brief, but comprehensive, overview of the efficacy
and safety of the oral loading regimen of propafenone for
cardioversion of recent-onset AFib.
CLINICAL TRIAL INFORMATION: EFFICACY
Single dose oral loading propafenone versus placebo.
Efficacy of the single oral loading dose of propafenone for
pharmacological cardioversion of recent-onset AFib has
been documented by different placebo-controlled trials (21–
23,25–29,31–33,35). The success rate varies from 58% to
83%, depending on the duration of AFib and follow-up
after administration of the drug (21–23,25–29,31–33,35).
The mean conversion time ranges from 110 6 59 to 287 6
352 min, depending on the duration of follow-up (21–
23,25–29,31–33,35). Boriani et al. (21) evaluated this reg-
imen (600 mg propafenone) in 240 patients with recent-
onset AFib (#7 days) in a multicenter, randomized,
placebo-controlled trial. Conversion to sinus rhythm was
significantly better in the propafenone treated patients with
3-h and 8-h conversion rates of 45% and 76% in the
propafenone group versus 18% and 37% in the placebo
group (p , 0.001 at both 3 h and 8 h). The conversion time
was 181 6 118 (mean 6 standard deviation [SD]) min in
the propafenone and 181 6 112 (mean 6 SD) min in the
placebo group (p 5 NS). Patients older than 80 years, those
with heart failure greater than New York Heart Association
functional class II, recent myocardial infarction (,6
months), unstable angina pectoris, complete bundle branch
block, previous electrocardiographic evidence of second- or
third-degree atrioventricular block or bifascicular block, sick
sinus syndrome, renal or hepatic failure, severe hypoxia,
severe metabolic disturbance, thyroid dysfunction, hypoka-
lemia, ventricular rate ,70 beats/min or on antiarrhythmic
therapy were excluded from the trial. More or less similar
exclusion criteria have been used in most of the trials
evaluating the efficacy of the single dose oral loading
regimen of propafenone.
The 600-mg dose of propafenone is used for oral loading
because it has been shown that 450 to 600 mg of oral
propafenone results in clinically effective plasma levels (41).
In another randomized, double-blind, placebo-controlled
trial (22) (n 5 55 patients), propafenone dose was weight-
titrated (450 mg for 50 to 64 kg, 600 mg for 65 to 85 kg and
750 mg for .85 kg body weight). Atrial fibrillation of #7
days was defined as recent-onset AFib. The patients were
followed for 24 h. The 2-h and 6-h conversion rates were
41% and 65%, respectively, and were significantly better
than those of the placebo group (8% and 31%) (p 5 0.005
and 0.015). The 12-h conversion rates were 69% in the
propafenone group and 42% in the placebo group with a
trend toward the difference (p 5 0.06). The 24-h conversion
rates were not significantly different between both groups
(propafenone, 79% vs. placebo, 73%). The number of patients
who received 450 mg (n 5 4) and 750 mg (n 5 3) doses was
not sufficient to empower the study to evaluate the effect of
weight-based dose adjustment on the efficacy of the drug.
In another randomized, placebo-controlled trial, Botto et
al. (23) compared 450-mg and 600-mg dosage regimens,
irrespective of the body weight of the patient (n 5 105).
Atrial fibrillation of #7 days was defined as recent-onset
AFib. The patients were followed for 24 h. The 2-h
conversion rate with the 600-mg dosage regimen was
significantly higher than it was for those with the 450-mg
dosage regimen (p 5 0.001) and the placebo (p 5 0.004).
The 450-mg regimen was not significantly better than the
placebo at 2 h. The 4-h, 8-h and 24-h conversion rates were
not significantly different between both dosage regimens.
Both 450-mg and 600-mg regimens were significantly
better than the placebo at 4 (p , 0.04 and p , 0.001) and
8 h (p , 0.01 and , 0.04) but not at 24 h. The time to sinus
conversion in the first 4 h was 176 6 56 (mean 6 SD) min
with the 450-mg regimen and 110 6 59 (mean 6 SD) min
with the 600-mg regimen. The trial demonstrated that the
600-mg regimen was more efficacious and resulted in earlier
conversion to sinus rhythm.
The efficacy of the single oral loading dose of the
propafenone administration has also been demonstrated in
nonrandomized trials (24,30). A nonrandomized study by
Ergene et al. (24) demonstrated that the 8-h conversion rate
with the use of a 600-mg single oral dose of propafenone for
the recent-onset subjects with AFib (,72 h) was 78%, with
a conversion time of 2.4 6 0.9 (mean 6 SD) h. In this
study, the duration of the AFib was found as a single,
significant predictor of the successful conversion to sinus
rhythm.
Oral versus intravenous regimens of propafenone. The
efficacy of the oral loading dose regimen versus the intrave-
Abbreviations and Acronyms
AFib 5 atrial fibrillation
AFl 5 atrial flutter
SD 5 standard deviation
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nous regimen of the propafenone administration for con-
version of patients with recent-onset AFib has been evalu-
ated in different randomized trials (27–29). The intravenous
regimen has been found superior in the first few hours of the
drug administration, but there has been no difference in the
efficacy of both of the regimens at the longer observation
periods. In a randomized, placebo-controlled trial involving
87 patients with recent-onset AFib (#7 days), Boriani et al.
(27) compared single oral loading dose regimen (600 mg)
with an intravenous regimen (2 mg/kg bolus followed by
0.0078 mg/kg/min). The 1-h conversion rate was signifi-
cantly higher with use of the intravenous regimen (28%)
than it was with the use of the oral regimen (3%) (p 5 0.05),
but 3- and 8-h conversion rates were not significantly
different between both regimens. The 3-h conversion rate
with the oral propafenone was 55% compared with 41%
with the intravenous propafenone (p 5 NS) and 10% with
the placebo (p , 0.001 oral; p , 0.02 intravenous). The 8-h
conversion rate with oral propafenone was 69% compared
with 66% with intravenous propafenone (p 5 NS) and 24%
with the placebo (p , 0.005 oral; p , 0.005 intravenous).
The conversion time was 163 6 114 (mean 6 SD) and
138 6 140 (mean 6 SD) min with oral and intravenous
regimens, respectively (p 5 NS).
In another randomized, placebo-controlled, crossover
trial, Botto et al. (28) compared the oral regimen (600 mg
single dose) with the intravenous regimen (2 mg/kg bolus
followed by 0.0078 mg/kg/min for 2 h) in 123 patients with
recent-onset AFib (,72 h). The patients were followed for
16 h. If AFib persisted at 8 h in the study (phase I), the
patients on the active drug regimens received the alternative
formulation in the dose similar to that used in the stage I
(crossover); the nonresponders in the placebo group were
continued on placebo (phase II). The intravenous regimen
was significantly superior to the oral loading regimen at 1-h
observation time (48% vs. 15%, p , 0.05) but not at longer
observation periods of 4 and 8 h. Rather, at 4 and 8 h, the
conversion rates were higher with the use of oral regimen
with a statistically significant difference at 8 h (71% vs. 50%
at 4 h, p 5 NS; 78% vs. 53% at 8 h, p , 0.03). In phase II,
at 1 h, the conversion rate in the nonresponders to the
intravenous regimen who were given the oral regimen was
similar to that in the nonresponders of the oral regimen who
were given the intravenous regimen (12% vs. 13%, p 5 NS)
but was significantly better at 4 and 8 h (65% vs. 13%, p 5
0.01 and 76% vs. 25%, p 5 0.004). The mean conversion
time within the first 4 h of the phase I was shorter with use
of the intravenous regimen than it was with the use of the
oral regimen (25 6 15 vs. 167 6 166 min, p , 0.001). In
this trial, the intravenous infusion was given for 2 h and was
not continued until the patient converted to sinus rhythm or
the study period was over, which could be a possible cause
of the lower success rates with the intravenous regimen at
the longer observation periods.
The efficacy of propafenone administration (both by
intravenous and oral routes) for short-term conversion of
AFib was analyzed in a meta-analysis published in 1998
(30). Twenty-seven trials were analyzed, of which 19 used
intravenous propafenone, 6 used oral loading propafenone
and 2 used a combination of oral and intravenous dosing
regimens. A total of 1,843 patients were treated with
propafenone in these trials. The meta-analysis compared the
efficacy of the oral regimens with that of the intravenous
regimens and of both the oral and intravenous regimens
combined with that of the placebo. It concluded that the
intravenous regimen, compared with the oral regimen,
resulted in a more rapid conversion to sinus rhythm (p ,
0.05 both at 1 and 2 h), but this advantage was no longer
apparent after 4 h of initiation of therapy. The patients
treated with propafenone (oral and intravenous combined)
were more likely to convert to sinus rhythm than those who
received placebo, with a treatment benefit of 31.5% at 4 h
(p , 0.01) and 32.9% at 8 h (p , 0.01). Propafenone
therapy (oral and intravenous combined) was not signifi-
cantly different from that of the placebo after 24 h of
administration of the drug. The efficacies of the oral and the
intravenous regimens were not compared with those of the
placebo individually.
Propafenone versus other oral loading drugs. The oral
loading regimen of propafenone for conversion of the
recent-onset AFib was compared with the oral loading
regimens of flecainide, quinidine and amiodarone, and it
was found to be as effective as that of the flecainide and
superior to those of quinidine and amiodarone (29,31–35).
The single oral regimen of propafenone (600 mg) was
compared with that of flecainide (300 mg) in a randomized,
placebo-controlled trial (31) involving 181 patients with
recent-onset AFib (#7 days). The 3-h conversion rates were
51%, 59% and 18%, and the 8-h conversion rates were 72%,
78% and 39% in the propafenone, flecainide and placebo
groups, respectively. The 3-h and 8-h conversion rates were
not statistically different between the propafenone and
flecainide treatment groups. The conversion time was
165 6 119 (mean 6 SD) min with propafenone use and
158 6 109 (mean 6 SD) min with flecainide use (p 5 NS).
In another randomized, placebo-controlled trial (n 5 87
patients) (33), the oral propafenone regimen (600 mg
loading, followed by 300 mg every 8 h for 48 h) was
compared with the digoxin plus quinidine regimen for
conversion of recent-onset AFib (AFib of #8 days). Quin-
idine administration was started 6 h after the initiation of
the intravenous administration of digoxin and was given as
a 300-mg dose followed by 150 mg every 3 h for 9 h and
then 150 mg every 8 h for a total loading of 1,350 mg. The
patients were followed for 48 h. The conversion to sinus
rhythm with the propafenone regimen was significantly
better than it was with the digoxin plus quinidine regimen
at 6 and 12 h (62% vs. 38%, p , 0.05 and 83% vs. 48%, p ,
0.05, respectively), but there was no difference at 24 and
48 h. The conversion time with the 48 h of follow-up was
167 6 238 (mean 6 SD) min for the propafenone group
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and 648 6 631 (mean 6 SD) min for the digoxin plus
quinidine group (p , 0.01).
Blanc et al. (34) compared the efficacy of the oral
propafenone with that of oral amiodarone for conversion of
recent-onset AFib (,2 weeks). In this randomized trial, the
patients in the propafenone group received a single oral
loading dose of 600 mg propafenone and, if necessary, a
repeat dose of 300 mg after 24 h; and the patients in the
amiodarone group received amiodarone 30 mg/kg and, if
necessary, a repeat dose of 15 mg/kg after 24 h. The patients
were followed for 48 h. The 4-h conversion rate was signifi-
cantly higher in the propafenone-treated patients (37% vs.
16%, p , 0.05), but by 24 h the difference was no longer
statistically significant (56% vs. 47%). The median conversion
time with propafenone use was significantly shorter than it was
with amiodarone (2.4 vs. 6.9 h, p 5 0.05). The success rate was
lower in this trial compared with the other propafenone trials,
and this could be secondary to the longer time duration used to
define the recent onset of AFib (two weeks). In a subgroup
analysis based on the duration of AFib, 84% of all the patients
with AFib of ,2 days duration converted to sinus rhythm
compared with 45% of those with AFib of $2 days (p 5
0.001) (34). The duration of AFib has been shown to be a
significant predictor for the successful conversion to sinus
rhythm with use of the single oral loading dose regimen of
propafenone (24).
Propafenone use in hypertension and structural heart
disease. In the trials where patients with systemic hyper-
tension and stable structural heart disease were included in
the study, it was demonstrated that the efficacy of
propafenone was not affected by the presence of systemic
hypertension or structural heart disease (21,24,35). In the
trial by Boriani et al. (21), of 119 patients in the
propafenone treatment arm, 37 had systemic hypertension,
and 32 had structural heart disease, including coronary
artery disease, valvular heart disease, cardiomyopathy and
congenital heart disease. The 8-h conversion rates in pa-
tients with hypertension, with structural heart disease and
without structural heart disease were 70%, 81% and 78%,
respectively (p 5 NS). In the trial by Ergene et al. (24),
most of the patients had systemic hypertension or structural
heart disease, including coronary artery disease, congestive
heart failure and mitral stenosis, and the presence of
systemic hypertension or structural heart disease did not
preclude the conversion to sinus rhythm.
CLINICAL TRIAL INFORMATION: SAFETY
The adverse effects reported with use of the single dose oral
loading regimen of propafenone were transient arrhythmia,
reversible QRS-complex widening, transient hypotension
and mild noncardiac side effects (21–29,31–35). The tran-
sient arrhythmias, chiefly at the time of conversion, included
appearance of atrial flutter (AFl), bradycardia, pauses and
junctional rhythm. No life-threatening proarrhythmic ad-
verse effects were reported. The effective concentration of
propafenone after an oral dose for patients with acute AFib
is significantly lower than that during the chronic adminis-
tration for patients with chronic AFib, which may be a
reason for the lack of serious adverse events with the use of
a single oral loading dose (37). All of the reported adverse
events, including proarrhythmic ones, were transient.
In most of the trials, the incidence of various proarrhyth-
mic adverse effects in propafenone treated patients was not
higher than that in the placebo treated patients. In the trial
by Boriani et al. (n 5 240 patients) (21), AFl or tachycardia
lasting $1 min appeared in eight patients (7%) receiving
propafenone and in seven patients (6%) receiving placebo,
regardless of heart disease status. Among these patients, in
all except one the atrioventricular conduction ratio was $2:1
with ventricular rates #140 beats/min; one patient in the
placebo group demonstrated 1:1 atrioventricular conduction
with a ventricular rate of 240 beats/min and experienced
syncope. Pauses in ventricular activity lasting for $2 s were
seen in one patient receiving propafenone and in three
receiving placebo. In another trial by Capucci et al. (33),
the AFl with $2:1 atrioventricular conduction ratios and
heart rates of #150 beats/min was noted in 4 of 29
propafenone recipients and in 4 of 29 placebo recipients. In
this trial, one patient in the propafenone group experienced
a syncopal episode, and the electrocardiographic recording
showed a wide-complex tachycardia at 220 beats/min,
which lasted a few seconds and ended spontaneously. One
month later, at an electrophysiological study, an AFl with
1:1 atrioventricular conduction at 220 beats/min was repro-
duced in this patient after the intravenous administration of
propafenone.
Propafenone, being principally metabolized by the liver,
may have an advantage of being useful in patients with renal
disease. In a nonrandomized study of 24 patients with AFib
and chronic renal failure (42), administration of intravenous
propafenone resulted in conversion to sinus rhythm in 21
patients without any serious adverse effects. However, the
safety of oral propafenone administration in chronic renal
failure cannot be generalized from a single trial with a small
number of patients who received the drug by a nonoral route.
Safety Antiarrhythmic Therapy Evaluation trial. The
results of the Safety Antiarrhythmic Therapy Evaluation
trial were published in 1999 (35). The primary end point of
this multicenter, placebo-controlled trial was to evaluate the
safety of the oral loading regimen of propafenone in restoring
the sinus rhythm in patients with recent-onset AFib com-
pared with the classical treatment. The trial enrolled 246
patients and randomly assigned them to one of the four
treatment groups: propafenone, digoxin plus propafenone,
digoxin plus quinidine and placebo. The propafenone dose
used was 600 mg for patients weighing .60 kg body weight
and 450 mg for patients ,60 kg body weight. After 6 h, a
second dose of 300 mg was given if AFib was persistent.
Digoxin was given intravenously at a dose of 0.5 mg at study
entry followed by 0.25 mg after 4 h and 0.125 mg after 8
and 12 h (total of 1 mg) to patients .60 kg body weight and
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0.125 mg at 4 h and 0.065 mg at 8 and 12 h (total of
0.755 mg) to patients ,60 kg body weight. Quinidine was
given 1 h after initiating the digoxin therapy at a dose of
275 mg every 2 h for a total dose of 1,100 mg. The adverse
events were classified as mild (transient and easily tolerated),
moderate (causing discomfort to the patient) and severe
(life-threatening or resulting in prolonged hospitalization).
None of the patients experienced severe clinical adverse
events. The most common arrhythmia noted was AFl in 13
propafenone treated, 12 digoxin plus propafenone treated, 9
digoxin plus quinidine treated and 3 placebo treated pa-
tients. All of these episodes were short lasting (,30 s), were
asymptomatic and were conducted with an atrioventricular
conduction ratio $2:1. None of the AFl episodes was
conducted to the ventricles with a 1:1 ratio. Four patients in
the digoxin plus propafenone group and one patient in the
digoxin plus quinidine group had asymptomatic ventricular
runs of 3 or 4 beats. A complete left bundle branch block
was detected in three patients in the propafenone group,
two patients in the digoxin plus propafenone group and two
patients in the digoxin plus quinidine group. The bundle
branch block resolved spontaneously in all patients during 4
to 8 h. A reversible, asymptomatic, Wenckebach II degree
sinus atrial exit block (pauses ,3 s) was observed at the time
of conversion in two patients in the propafenone group and
in two patients in the digoxin plus quinidine group. Mild
arterial hypotension developed in five patients in the
propafenone group, one patient in the digoxin plus
propafenone group, one patient in the digoxin plus quini-
dine group and one patient in the placebo group. None of
these episodes was severe enough to require any pharmaco-
logical intervention. The noncardiac side effects were mild
and, in the propafenone treated patients, consisted of
nausea, headache, gastrointestinal disturbances, dizziness
and paresthesia. The side effects in the propafenone group
were not significantly different from those in other treat-
ment groups.
Concomitant use of an atrioventricular node-blocking
drug. A need for concomitant therapy with the agents that
block the atrioventricular node is unclear at the present time
because patients receiving these types of agents were ex-
cluded from most of the trials. Although it could be
speculated that if an AFl develops, the beta-blocking and
calcium channel blocking effects of the propafenone may
protect against 1:1 atrioventricular conduction; however,
there is a minimum possibility that rapid atrioventricular
conduction may develop, resulting in a fast ventricular
response. Therefore, to abate any possibility of 1:1 atrioven-
tricular conduction in case AFl develops, it may be prudent
to administer an atrioventricular node-blocking drug before
propafenone loading or to keep the patients at bed rest
afterward (13). Many physicians do administer low-dose
propranolol or another beta-blocker to the patients being
treated with the oral propafenone in order to avoid AFl with
1:1 conduction, but studies need to be done to evaluate
whether the coadministration of a beta-blocker with the oral
loading dose of the propafenone will have added benefit in
addition to that provided by the inherent atrioventricular
node-blocking properties of the propafenone.
CONTRAINDICATIONS
Based on the previous experience with propafenone, its admin-
istration is contraindicated in patients with congestive heart
failure; severe systolic dysfunction; sinoatrial, atrioventricular or
intraventricular disorders of impulse conduction; sinus node
dysfunction; hypotension; unstable angina; acute or recent
myocardial infarction; severe hepatic or renal failure; hypoka-
lemia; thyroid dysfunction; bronchospastic disorder; and severe
metabolic disturbances (43–46). Patients with these conditions
were excluded from almost all the trials evaluating efficacy and
safety of the oral loading dose regimen of propafenone for
conversion of recent-onset AFib.
CONCLUSIONS
Because of its high rate of effectiveness, a relative rapid effect
within 2 to 3 h and the simplicity of administration, the
single oral loading dose of propafenone may be considered
to be among the first-line treatments used for conversion of
recent-onset AFib. Most of the data on the use of single oral
loading of propafenone is for a single dose of 600 mg. The
success rate of this regimen ranges from 56% to 83%,
depending on the duration of the AFib and follow-up after
drug administration. The conversion time varies from
110 6 59 to 287 6 352 min, depending on the duration of
the observation after drug administration. The single oral
loading dose of propafenone is significantly more efficacious
than placebo in the first 8 h after administration of the drug,
but the difference does not remain statistically significant at
24 h.
The use of the oral loading regimen of propafenone in
patients with hypertension and stable structural heart dis-
ease is not supported by a large body of data, although, in
trials that recruited patients with hypertension and stable
structural heart disease, the efficacy and side effect profile of
this regimen in these patients was not different from the
patients without hypertension or structural heart disease.
The data on the use of the single oral loading dose of
propafenone in patients already taking propafenone or
another antiarrhythmic drug has not been reported.
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